Compare EPR Properties (EPR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Zoetis Inc — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 7.2× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and Zoetis Inc for 70 Days on average.
| EPR | ZTS | |
|---|---|---|
Market Cap | $4.17B | $30.20B |
Volume | 992,716 | 6,175,327 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $147.53 |
52-Week Low | $48.71 | $69.09 |
Typical Hold Time | 46 Days | 70 Days |
Enterprise Value | $7.68B | $37.76B |
Dividend Yield | 6.84% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.41, up 0.61% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT reported strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though Q1 2026 earnings missed expectations. Recent news highlights its appeal for income investors, with monthly dividends and diversification into theme parks and fitness.
Outlook is mixed: analyst consensus is a Buy with a $65.50 target, but technicals and a projected 2026 net income decline pose risks. The stock offers value at a P/E of 17.44 and high yield, yet investors face headwinds from rising Treasury yields and competitive pressures in the net lease REIT sector.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
